Annalise CXR is CE marked for use in the UK and Europe
Annalise CXR is now CE marked and available for clinical use as a medical device in the UK and Europe.
Intended to assist clinicians with the interpretation of radiological imaging studies, Annalise CXR is annalise.ai’s first comprehensive solution to market. The solution can detect 124 findings, assisting clinicians to diagnose with confidence. The solution seamlessly integrates with regular workflows, highlighting findings picked up on chest-x-rays for review by the radiologist.
annalise.ai CEO Dimitry Tran said: “Gaining CE mark for Annalise CXR in our first year of business is testament to the team’s focus on creating safe, ethical and clinically indispensable AI solutions. We look forward to working with regulatory authorities around the world as Annalise CXR enters new markets, and our company develops future comprehensive medical imaging solutions over the coming years.”
Learn more about Annalise CXR.
About Harrison.ai
Harrison.ai is a global healthcare technology company that enhances clinician capacity and patient care through AI automation. Clinician-led and patient-first, our suite of solutions supports earlier, more accurate diagnoses and seamlessly integrates into clinical workflows.Harrison.ai solutions are available in 40+ countries and to half of all Australian radiologists. They are clinically deployed at 1,000+ customer sites globally, including 40+ NHS Trusts and all public emergency departments in Hong Kong. With 3,400+ clinicians using our tools, Harrison.ai has impacted more than 7 million patients’ lives to date.
